Comparative Effects of Efaroxan and b‐Carbolines on the Secretory Activity of Rodent and Human b Cells
- 1 December 2003
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1009 (1) , 167-174
Abstract
Abstract: The pancreatic b‐cell expresses an imidazoline‐binding site that is involved in the regulation of insulin secretion. This site is pharmacologically atypical in comparison with the I1 and I2 sites described in other tissues, and it has been classified as I3. The structural requirements for binding of ligands to the I3 site have not been fully defined, although a range of synthetic I3 ligands have been characterized in functional terms. Evidence has been presented that an endogenous I3 ligand may exist, because extracts of brain contain an active principle that stimulates insulin secretion in a manner consistent with the involvement of I3 sites. The active component has not been identified but has been equated with the long‐sought clonidine displacing substance (CDS) that is proposed as the endogenous ligand for imidazoline‐binding sites. Recent evidence has indicated that one active component of CDS may be a b‐carboline, but it is not known whether b‐carbolines can stimulate insulin secretion. Thus, we have studied the effects of b‐carbolines on insulin secretion and cytosolic Ca21 levels in rodent and human islet cells. The results reveal that harmane, pinoline, and norharmane cause a dose‐ and glucose‐dependent increase in insulin secretion but show that this response differs in a number of ways from that elicited by the well‐characterized I3‐agonist, efaroxan. Thus, b‐carbolines represent a new class of insulin secretagogues, although it remains unclear whether their action is mediated solely by I3 sites in the b cell.Keywords
This publication has 19 references indexed in Scilit:
- Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca2+-dependent exocytosis in pancreatic α- and β-cellsEuropean Journal of Pharmacology, 2003
- Imidazolines as efficacious glucose-dependent stimulators of insulin secretionEuropean Journal of Medicinal Chemistry, 2003
- Identification of the monomeric G‐protein, Rhes, as an efaroxan‐regulated protein in the pancreatic β‐cellBritish Journal of Pharmacology, 2002
- Clonidine-Displacing Substance Reduces Glucagon Secretion from Mouse Pancreatic α-Cells by KATP-Channel-Independent Inhibition of ExocytosisBiochemical and Biophysical Research Communications, 2001
- β-carboline binding to imidazoline receptorsDrug and Alcohol Dependence, 2001
- Harmane produces hypotension following microinjection into the RVLM: possible role of I1‐imidazoline receptorsBritish Journal of Pharmacology, 2000
- Multiple effector pathways regulate the insulin secretory response to the imidazoline RX871024 in isolated rat pancreatic isletsBritish Journal of Pharmacology, 1999
- Clonidine-Displacing Substance and Its Putative Role in Control of Insulin Secretion: A MinireviewGeneral Pharmacology: The Vascular System, 1998
- The effect of the putative endogenous imidazoline receptor ligand, clonidine‐displacing substance, on insulin secretion from rat and human islets of LangerhansBritish Journal of Pharmacology, 1997
- Stimulation of insulin secretion by efaroxan may involve interaction with potassium channelsEuropean Journal of Pharmacology, 1990